UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Molecular and Immunohistochemical Testing in Mesothelioma and Other Mesothelial Lesions

Archives of pathology & laboratory medicine (1976), 2024-05, Vol.148 (5), p.e77-e89

2024

Volltextzugriff (PDF)

L1CAM expression in cystic mesothelial lesions: a comparison with adenomatoid tumours, well‐differentiated papillary mesothelial tumours and malignant mesotheliomas

Histopathology, 2021-08, Vol.79 (2), p.272-274

2021

Volltextzugriff (PDF)

Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays

Human pathology, 2019-05, Vol.87, p.11-17

2019

Volltextzugriff (PDF)

Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas

Archives of pathology & laboratory medicine (1976), 2018-12, Vol.142 (12), p.1549-1553

2018

Volltextzugriff (PDF)

Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study

Human pathology, 2018-02, Vol.72, p.160-166

2018

Volltextzugriff (PDF)

BAP1 and Claudin-4, But Not MTAP, Reliably Distinguish Borderline and Low-grade Serous Ovarian Tumors From Peritoneal Mesothelioma

International journal of gynecological pathology, 2023-03, Vol.42 (2), p.159-166

2023

Volltextzugriff (PDF)

Gene of the month: BAP1

Journal of Clinical Pathology, 2016-09, Vol.69 (9), p.750-753

2016

Volltextzugriff (PDF)

Tumours associated with BAP1 mutations

Pathology, 2013-02, Vol.45 (2), p.116-126

2013

Volltextzugriff (PDF)

Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study

Human pathology, 2014-07, Vol.45 (7), p.1529-1540

2014

Volltextzugriff (PDF)

Role of evaluating tumor‑infiltrating lymphocytes, programmed death‑1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma

International journal of oncology, 2019-11, Vol.55 (5), p.1157-1164

2019

Volltextzugriff (PDF)

Pleural neoplastic pathology

Respiratory medicine, 2015-08, Vol.109 (8), p.931-943

2015

Volltextzugriff (PDF)

Inflammasome Modulation by Chemotherapeutics in Malignant Mesothelioma

PloS one, 2015-12, Vol.10 (12), p.e0145404-e0145404

2015

Volltextzugriff (PDF)

PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma

The American journal of surgical pathology, 2010-05, Vol.34 (5), p.627-635

2010

Volltextzugriff (PDF)

Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma

Modern pathology, 2020-02, Vol.33 (2), p.217-227

2020

Volltextzugriff (PDF)

Connective tissue growth factor and β-catenin constitute an autocrine loop for activation in rat sarcomatoid mesothelioma

The Journal of pathology, 2014-08, Vol.233 (4), p.402-414

2014

Volltextzugriff (PDF)

Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma

PloS one, 2011-04, Vol.6 (4), p.e18232

2011

Volltextzugriff (PDF)

Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: Ten Years of Clinical Experience in Relation to International Guidelines

Archives of pathology & laboratory medicine (1976), 2018-08, Vol.142 (8), p.893-901

2018

Volltextzugriff (PDF)

Use of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions

Archives of pathology & laboratory medicine (1976), 2020-02, Vol.144 (2), p.185-188

2020

Volltextzugriff (PDF)

Glypican-1 immunohistochemistry does not separate mesothelioma from pulmonary adenocarcinoma

Modern pathology, 2018-09, Vol.31 (9), p.1400-1403

2018

Volltextzugriff (PDF)

Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses

Journal of clinical pathology, 2016-08, Vol.69 (8), p.706-712

2016

Volltextzugriff (PDF)

Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors

The American journal of surgical pathology, 2012-04, Vol.36 (4), p.629-639

2012

Volltextzugriff (PDF)

The Diagnostic Utility of p16 FISH and GLUT-1 Immunohistochemical Analysis in Mesothelial Proliferations

American journal of clinical pathology, 2011-04, Vol.135 (4), p.619-627

2011

Volltextzugriff (PDF)

Well-differentiated papillary mesothelioma of the female peritoneum: a clinicopathologic study of 26 cases

The American journal of surgical pathology, 2012-01, Vol.36 (1), p.117-127

2012

Volltextzugriff (PDF)

BAP1 Loss is a Useful Adjunct to Distinguish Malignant Mesothelioma Including the Adenomatoid-like Variant From Benign Adenomatoid Tumors

Applied immunohistochemistry & molecular morphology, 2020-01, Vol.28 (1), p.67-73

2020

Volltextzugriff (PDF)

Well-differentiated papillary mesothelioma: a clinicopathological and immunohistochemical study of 18 cases with additional observation

Histopathology, 2013-04, Vol.62 (5), p.805-813

2013

Volltextzugriff (PDF)

1 – 25 von 418

Suche als RSS-Feed

Aktive Filter

SpracheJapanisch

ThemaPathology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(405)
Mit Volltextzugriff
(360)

Publikationsform

Artikel
(418)

Sprache

Englisch
(417)
Chinesisch
(1)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Molecular and Immunohistochemical Testing in Mesothelioma and Other Mesothelial Lesions

L1CAM expression in cystic mesothelial lesions: a comparison with adenomatoid tumours, well‐differentiated papillary mesothelial tumours and malignant mesotheliomas

Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays

Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas

Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study

BAP1 and Claudin-4, But Not MTAP, Reliably Distinguish Borderline and Low-grade Serous Ovarian Tumors From Peritoneal Mesothelioma

Gene of the month: BAP1

Tumours associated with BAP1 mutations

Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study

Role of evaluating tumor‑infiltrating lymphocytes, programmed death‑1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma

Pleural neoplastic pathology

Inflammasome Modulation by Chemotherapeutics in Malignant Mesothelioma

PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma

Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma

Connective tissue growth factor and β-catenin constitute an autocrine loop for activation in rat sarcomatoid mesothelioma

Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma

Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: Ten Years of Clinical Experience in Relation to International Guidelines

Use of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions

Glypican-1 immunohistochemistry does not separate mesothelioma from pulmonary adenocarcinoma

Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses

Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors

The Diagnostic Utility of p16 FISH and GLUT-1 Immunohistochemical Analysis in Mesothelial Proliferations

Well-differentiated papillary mesothelioma of the female peritoneum: a clinicopathologic study of 26 cases

BAP1 Loss is a Useful Adjunct to Distinguish Malignant Mesothelioma Including the Adenomatoid-like Variant From Benign Adenomatoid Tumors

Well-differentiated papillary mesothelioma: a clinicopathological and immunohistochemical study of 18 cases with additional observation

Aktive Filter

Suchergebnisse filtern